La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs
Lahr RM. et al, (2017), eLife, 6
The RNA-binding protein LARP1 is a cancer therapeutic target
Ghazaly EA. et al, (2017), CANCER RESEARCH, 77
Protein interactions involving LARP1 in chemotherapy resistant ovarian cancer cells
Stavraka C. et al, (2017), CANCER RESEARCH, 77
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
Blagden SP., (2016), Annals of Oncology
Loss of LARP4B, an early event in the tumorigenesis of brain cancer?
Blagden S. et al, (2016), TRANSLATIONAL CANCER RESEARCH, 5, S1196 - S1199
The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer.
Hopkins TG. et al, (2016), Nucleic Acids Res, 44, 1227 - 1246
A phase Ib study of NUC1031 and carboplatin for patients with recurrent ovarian cancer.
Blagden SP. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34
SOCQER-2 Study: Preliminary analysis of multicentre recruitment after surgery in advanced ovarian cancer
Kumar S. et al, (2016), INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 26, 832 - 833
Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies.
Gungor H. et al, (2015), J Nucl Med, 56, 1828 - 1835
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
Bowtell DD. et al, (2015), Nat Rev Cancer, 15, 668 - 679
The La-Related Proteins, a Family with Connections to Cancer
Blagden None. and stavraka C., (2015), Biomolecules
Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer.
Blagden None., (2015), Frontier in oncology
LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression
Blagden None. et al, (2015), Oncogene
The next steps in improving the outcomes of advanced ovarian cancer.
Blagden None. et al, (2015), Womens' health
LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression.
Mura M. et al, (2015), Oncogene, 34, 5025 - 5036
The La-related protein 1-specific domain repurposes HEAT-like repeats to directly bind a 5'TOP sequence.
Lahr RM. et al, (2015), Nucleic Acids Res, 43, 8077 - 8088
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM. et al, (2015), Lancet Oncol, 16, 928 - 936
The next steps in improving the outcomes of advanced ovarian cancer.
Openshaw MR. et al, (2015), Womens Health (Lond), 11, 355 - 367
Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer.
Borley J. et al, (2015), BJOG, 122, 843 - 849